Ownership and insider activity for Sarepta Therapeutics, Inc. (SRPT): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases.
Price
| Price | $18.99 (closing price, November 4, 2026) |
| Market Cap | $2.0B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $122.4M | $599.7M | $370.8M | $835.1M | $1.50B | $2.12B | $966.8M | $428.4M | $1.10B | $801.3M |
| Short-term Investments | $195.4M | $479.4M | $803.1M | $289.7M | $435.9M | 0 | $1.02B | $1.25B | $251.8M | $138.4M |
| Receivables | $5.2M | $29.5M | $49.0M | $93.9M | $138.6M | $172.7M | $261.6M | $437.0M | $649.7M | $519.6M |
| Inventory | $12.8M | $83.6M | $125.4M | $171.4M | $232.0M | $186.2M | $204.0M | $322.9M | $750.0M | $914.7M |
| Total Current Assets | $373.5M | $1.23B | $1.43B | $1.47B | $2.49B | $2.60B | $2.56B | $2.58B | $3.07B | $2.54B |
| Property, Plant & Equipment | $37.8M | $43.2M | $97.0M | $167.6M | $282.2M | $236.7M | $245.0M | $357.1M | $488.6M | $470.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $8.1M | $14.4M | $11.6M | $12.5M | $13.6M | $14.2M | $7.6M | $29.6M | $26.9M | $28.9M |
| Total Assets | $424.1M | $1.31B | $1.64B | $1.82B | $2.98B | $3.15B | $3.13B | $3.26B | $3.96B | $3.35B |
| Accounts Payable | $29.7M | $8.5M | $33.8M | $68.1M | $111.1M | $76.7M | $95.9M | $164.9M | $214.4M | $280.8M |
| Short-term Debt | $10.1M | $6.2M | 0 | $7.8M | $20.9M | 0 | 0 | $105.5M | 0 | 0 |
| Total Current Liabilities | $75.4M | $88.3M | $173.7M | $264.8M | $416.0M | $452.7M | $619.6M | $653.7M | $731.7M | $1.10B |
| Long-term Debt | $6.0M | $424.9M | $420.6M | $681.9M | $992.5M | $1.10B | $1.54B | $1.13B | $1.14B | $829.0M |
| Total Liabilities | $87.4M | $518.7M | $609.8M | $1.00B | $2.22B | $2.22B | $2.74B | $2.41B | $2.44B | $2.21B |
| Retained Earnings | -$1.17B | -$1.22B | -$1.58B | -$2.29B | -$2.85B | -$3.21B | -$3.91B | -$4.45B | -$4.21B | -$4.88B |
| Total Equity | $336.7M | $789.2M | $1.03B | $818.2M | $761.8M | $928.0M | $384.9M | $859.3M | $1.53B | $1.14B |
| Total Debt | $16.1M | $431.1M | $420.6M | $737.5M | $1.09B | $1.15B | $1.62B | $1.40B | $1.34B | $1.04B |
| Net Debt | -$301.7M | -$648.0M | -$753.4M | -$387.3M | -$844.8M | -$962.4M | -$372.0M | -$279.4M | -$11.7M | $100.1M |
| Working Capital | $298.1M | $1.14B | $1.25B | $1.20B | $2.07B | $2.15B | $1.94B | $1.93B | $2.34B | $1.44B |
Financial Health
| Debt / Equity | 0.68 |
| Current Ratio | 4.42 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -0.90 |
Profitability
| Return on Equity | -9.96% |
| Return on Invested Capital | -5.33% |
| Return on Assets | -4.29% |
| Gross Margin | 58.56% |
| Operating Margin | -7.26% |
| Net Margin | -6.93% |
Related companies: ALNY · IONS · PTCT · DYN
Explore sector: Healthcare · Biotechnology
More sections of SRPT: Overview · Financials · Valuation · Estimates · Technical
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks